Subscribe Become an Author Add Company Sign Up Log In

A Running List Of Covid-19 Treatments And Vaccines In Development

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is is a positive sense, single stranded RNA beta coronavirus, a member of Beta-CoV lineage B (subgenus Sarbecovirus). 

Covid-19 Drug Repurposing Landscape

COVID-19 represents a global health threat and it is a serious driver of possible economic crisis, so curbing the current ongoing outbreak is the matter of top priority for most health organizations and biotech companies. 

In order to follow the quick pace of progress in the area of coronavirus treatments and vaccines development we decided to create and maintain a list of key programs and projects, with data about companies and specific clinical trials where available. 

The majority of molecules in the below list represent the case of so-called drug repurposing, when a molecule has prior known activity against some other indication. Drug repurposing is the most efficient option to come up with a new cure quickly -- a lot of safety data and other studies outcomes are already available for the molecule which allows to substantially accelerate the drug development process.

Most of the potential treatments against the coronavirus Covid-19 fall within two categories: treatments for the respiratory symptoms, and inhibitors of the viral growth.

Vaccines are meant to create prior immunity in a patient, and are meant to prevent future disease risks. Much as important they are to tackle the coronavirus problem in general, they will take substantially longer time to develop (over half-a-year vs several months for a suitable repurposing candidate), therefore they are considered more of a future long-term strategy, rather than an emergency measure to fight the ongoing coronavirus outbreak.

 

Disclaimer: This post is not medical advice of any kind, it is meant exclusively to communicate research news about current biopharmaceutical efforts globally. Please, consult with your doctor for any treatments or medications at all times. 

Editor’s note: while we are trying hard to update this list frequently to keep it up-to-date, the area is changing fast and new information arrives constantly, so we can’t guarantee the completeness or freshness of the information in future. 

 

Table 1. Drug Repurposing Treatments/combinations In Development

Candidate MoA / indication Status/clinical trials Sponsor/Producer
Kaletra (lopinavir/ritonavir)

Combinational therapy
HIV protease inhibitor

HIV-1 infection
> 10 latest stages clinical studies (Including combinations with other drugs)
NCT04321174
NCT04255017
NCT04307693
AbbVie
COVID-19 antibody therapy antibody Development stage AbCellera
Eli Lilly
TMC-310911 (ASC-09)

TMC-310911
Novel investigational protease inhibitor (structurally similar to darunavir) Clinical Studies of Combinational Therapies

NCT04261907
NCT04261270
Ascletis,
First Affiliated Hospital of Zhejiang University, Tongji Hospital
Ganovo (Danoprevir)

Danoprevir
Hepatitis C virus protease inhibitor
Hepatitis C
Phase 4 Clinical Study
In combination with other drugs
NCT04291729
Ascletis,
The Ninth Hospital of Nanchang
Galidesivir (BCX4430)

Galidesivir
Nucleoside RNA polymerase inhibitor
Yellow Fever
Advanced development stage BioCryst Pharmaceuticals
BOLD-100 Inhibit stress-induced upregulation of GRP78

Cancer drug
Suggested Bold Therapeutics
Leronlimab (PRO 140)
Humanized monoclonal antibody
Binds to CCR5

HIV, cancer
Initiation of Phase 2 Clinical Study CytoDyn Inc.
Ivermectin

Ivermectin
Anti-parasitic drug Preclinical study
 
Doherty Institute

Monash University in Australia
Fingolimod

Fingolimod
Sphingosine 1-phosphate receptor modulator
Multiple sclerosis
Phase 2 Clinical Study in China

NCT04280588
First Affiliated Hospital of Fujian Medical University
Thalidomide

Thalidomide
MoA is not fully understood Phase 2 Clinical Trials in China
NCT04273581
NCT04273529
First Affiliated Hospital of Wenzhou Medical University
Remdesivir (GS - 5734)

Remdesivir
Block RNA polymerase
Ebola
Orphan Drug Designation for Gilead

9 clinical studies worldwide
NCT04323761
NCT04257656
NCT04315948
Gilead Sciences
Truvada (emtricitabine + tenofovir)
Combinational therapy
Non-nucleoside reverse transcriptase inhibitors
HIV infection
In preparation Gilead Sciences
Triazavirin

Triazavirin
inhibits RNA synthesis Phase 3 Clinical Study in China

ChiCTR2000030001
Health commission of Heilongjiang province
Baricitinib

Baricitinib
JAK/NAK inhibitor

Rheumatic Disease
Phase 3 Clinical Study in Italy

NCT04320277
Hospital of Prato
Prezista/ Prezcobix (darunavir + cobicistat)
Combinational therapy
Protease inhibitor
HIV infection
Phase 3 Clinical Studies
NCT04304053 in Spain

3Cclinical tStudies in China
NCT04252274
ChiCTR2000030259
ChiCTR2000029541
Janssen Pharmaceuticals
Fundacio Lluita Contra la SIDA,
Medical Institutions in China
Chloroquine

Chloroquine
Endosomal acidification fusion inhibitor
Anti-malarial
> 10 studies worldwide
> 10 Clinical Studies in China
ChiCTR2000029609
NCT04261517
Medical institutions worldwide
Azithromycin

Azithromycin
Antibiotic > 10 trials in combination with other drugs
NCT04322396
NCT04321278
NCT04322123
Medical institutions worldwide
Remestemcel-L
Mesenchymal stromal cell (MSC)
Migrate to the site of inflammation to reduce the production of pro-inflammatory cytokines.

Indication: Acute Graft versus Host Disease
Phase III Clinical Trials

NCT04371393
Mesoblast, Inc. / Icahn School of Medicine at Mount Sinai
Favipiravir (T-705)

Favipiravir
Block RNA polymerase
Flu drug
Approved in China

Clinical studies in China, Japan, and Italy
ChiCTR2000029996
ChiCTR2000030894
Produced by Fujifilm Toyama Chemical
Kevzara (sarilumab)

Monoclonal antibody
Anti - IL-6

Rheumatoid arthritis
Phase 2, 3 Clinical Study
NCT04315298
Regeneron Pharmaceuticals,
Sanofi
EIDD-2801

EIDD-2801
Block RNA polymerase Suggested Ridgeback Biotherapeutics

Developed by Emory University
Activase Tissue plasminogen activator

Stroke drug
Suggested Roche
(Genentech)
Actemra (tocilizumab)

Monoclonal antibody
anti-IL-6R


Rheumatoid arthritis
Approved in China

5 Clinical Studies in Denmark, Italy, China
NCT04317092
NCT04331795
Roche,
Medical institutions worldwide
Umifenovir (Arbidol)

Umifenovir
Membrane fusion inhibitor Latest stages clinical studies in China
(Including combinations with other drugs)
ChiCTR2000029621
NCT04260594
Ruijin Hospital,
Other institutions in China
TAK-888
(Plasma-derived antibodies)
Polyclonal
hyperimmune globulin (H-IG)
Development stage Takeda
Ruxolitinib (Jakafi, Jakavi)

Ruxolitinib
Inhibitor of Janus-associated kinases (JAK1 and JAK2)
Myelofibrosis
Clinical Study in China
Ruxolitinib combined with stem cell therapy
ChiCTR2000029580
Tongji Hospital, Hubei, China
Tongji Hospital, Hubei, China
Manufacturer - Incyte Corporation
Camostat mesylate (Foypan)

Foypan
inhibit SARS-CoV-2 Spike protein-initiated membrane fusion Phase 1, 2 Clinical Study in Germany
NCT04321096
University of Aarhus
Manufactured in Japan
Nafamostat mesylate (Fusan)

Nafamostat
inhibit SARS-CoV-2 Spike protein-initiated membrane fusion
Acute pancreatitis
Completed preclinical study in Japan University of Tokyo
Hydroxychloroquine
(Plaquenil)

Hydroxychloroquine
Endosomal acidification fusion inhibitor
Anti-malarial
Rheumatoid arthritis treatment
> 10 Clinical Studies worldwide
10 Clinical Studies in China
NCT04321278
NCT04261517
ChiCTR2000029868
 

 

Table 2. Vaccines In Development

Candidate Status/clinical trials Sponsor/Producer
Coronavirus vaccine
(self-replicating RNA)
Preclinical development Arcturus Therapeutics
BNT-162
mRNA vaccine
Preclinical development BioNTech in collaboration with Pfizer
Recombinant Coronavirus vaccine Phase II Clinical Trials
NCT04313127
NCT04341389
CanSino Biologics Inc.
Protein-based vaccine (S-Trimer) Preclinical development Clover Biopharmaceuticals
mRNA based coronavirus vaccine Preclinical development

Curevac

anti-SARS antibodies Preclinical development Distributed Bio
Vaccine adjuvant CpG 1018 Preclinical development
(adjuvant to S-Trimer vaccine)
Dynavax Technologies Corp
anti-SARS antibodies Preclinical development

Emergent BioSolutions

Coronavirus vaccine

Preclinical development

Geovax

Vaccine adjuvant Preclinical development
(adjuvant to S-Trimer vaccine)
GlaxoSmithKline
Self-assembling vaccine (SAV) Preclinical development HaloVax (Hoth Therapeutics + Voltron Therapeutics)
Coronavirus vaccine Preclinical development Heat Biologics Inc.
INO-4800
DNA-based vaccine
Phase I Clinical Trials

NCT04336410
Inovio Pharmaceuticals
Coronavirus vaccine Preclinical development Johnson & Johnson
mRNA-1273 Phase I Clinical Trials

NCT04283461
NIAID in collaboration with Moderna Therapeutics
NVX-CoV2373
Coronavirus vaccine
Preclinical development Novavax Inc
mRNA vaccine Preclinical development Translate Bio Inc in collaboration with Sanofi Pasteur
Oral recombinant vaccine Preclinical development Vaxart Inc.
VIR-7831, VIR-7832
anti-SARS antibodies

Preclinical development

Vir Biotechnology
in collaboration with GSK
anti-SARS monoclonal antibodies Preclinical development Vir Biotechnology partnerships with Biogen, WuXi Biologics

siRNA Preclinical development

Alnylam and Vir Biotechnology

Tuberculosis vaccine - BCG Phase III Clinical Trials in 6 countries

NCT04328441
NCT04327206
 

Like what you are reading? Subscribe to get new posts from this website 1-2 times per month.

Subscribe

Intelligence Platform